Newsome SD, et al. A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis. Abstract 60. ECTRIMS 11-13 sept 2019, Stockholm, Zweden.
Nederlandse Hersenbank: doodsoorzaak te vaak onjuist
apr 2017 | Bewegingsstoornissen, Dementie, Multipele Sclerose